Phase I, multicentre, dose‐escalation trial of monotherapy with milatuzumab (humanized anti‐CD 74 monoclonal antibody) in relapsed or refractory multiple myeloma
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Summary: CD 74, expressed in multiple myeloma (MM), was evaluated as a target for immunotherapy with milatuzumab (a humanized anti‐CD 74 antibody). In a multicentre dose escalation study, 25 patients with advanced MM received milatuzumab doses of 1·5 (N = 8), 4·0 (N = 9), 8·0 (N = 4) or 16·0 mg/kg (N = 4) administered twice weekly x 4. They had a median of 5 prior treatments (17 post ≥1 stem cell transplantation) and were refractory (N = 7) or relapsed (N = 18) with generally short‐lived responses to last treatment (median 4·0 months). After increasing prophylactic medications and slowing administration, infusions were well tolerated (National Cancer Institute‐Common Terminology Criteria v3 toxicity Grades 1–2) with no dose‐limiting toxicity at higher doses. Only one patient developed borderline positive human anti‐milatuzumab antibody titres of uncertain clinical significance. Although milatuzumab was rapidly cleared from circulation with little serum accumulation and low trough levels, B‐cell levels were moderately decreased with treatment (median decrease, 34%). There were no objective responses by European Group for Blood and Marrow Transplantation criteria, but 5 of 19 patients (26%) who completed treatment in this heavily pretreated and generally refractory group had stable disease for ≥3 months post‐treatment (one continuing for 17 months). Disease stabilization and evidence of pharmacodynamic activity support further development for use in combination with other agents or as a drug conjugate. (Clinicaltrials.gov identifier: NCT00421525)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450 · cited 1×
“…25 September 2013 doi: 10.1111/bjh.12565 ª 2013 John Wiley & Sons Ltd British Journal of Haematology, 2013, 163, 478–486 and pegylated liposomal doxorubicin (Richardson et al, 2005; Rajkumar et al, 2006; Dimopoulos et al, 2007; Orlowski et al, 2007; Weber et al, 2007; San Miguel et al, 2008).”
BackgroundInfluentialLenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Self-citationRajkumar, S. V., Blood, E., Vesole, D., Fonseca, R., & Greipp, P. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0221 · Cited by 865 · cited 1×
“…25 September 2013 doi: 10.1111/bjh.12565 ª 2013 John Wiley & Sons Ltd British Journal of Haematology, 2013, 163, 478–486 and pegylated liposomal doxorubicin (Richardson et al, 2005; Rajkumar et al, 2006; Dimopoulos et al, 2007; Orlowski et al, 2007; Weber et al, 2007; San Miguel et al, 2008).”
BackgroundInfluentialZonder, J. A., Mohrbacher, A. F., Singhal, S., van Rhee, F., Bensinger, W. I., Ding, H., Fry, J., Afar, D. E. H., & Singhal, A. K. (2012) · Blood · doi:10.1182/blood-2011-06-360552 · Cited by 342
Cited by
The biological function and significance of CD74 in immune diseases
Su, H., Na, N., Zhang, X., & Zhao, Y. (2017) · Inflammation Research · doi:10.1007/s00011-016-0995-1 · Cited by 306
Sumaiya, K., Langford, D., Natarajaseenivasan, K., & Shanmughapriya, S. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108024 · Cited by 299
The multifaceted roles of the invariant chain CD74 — More than just a chaperone
Schröder, B. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.03.026 · Cited by 284
New developments for antibody-drug conjugate-based therapeutic approaches
de Goeij, B. E., & Lambert, J. M. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.02.008 · Cited by 256
MIF-Dependent Control of Tumor Immunity
Noe, J. T., & Mitchell, R. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.609948 · Cited by 198
Analysis of CD74 Occurrence in Oncogenic Fusion Proteins
(2023) · doi:10.3390/ijms242115981 · Cited by 14
Metadata
- Authors
- Kaufman, J. L., Niesvizky, R., Stadtmauer, E. A., Chanan‐Khan, A., Siegel, D., Horne, H., Wegener, W. A., & Goldenberg, D. M.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2013-09-25
- Volume
- 163
- Issue
- 4
- Pages
- 478-486
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2017357058
- Cited by
- 125
- References
- 6
- FWCI
- 6.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.